Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Ozempic has a list price of around $935 a month while Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account. The negotiated price ...

WASHINGTON — (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to ... “Some folks have to skip a dose in their prescription so they can make a prescription last ...

Corbis / Corbis via Getty Images Medicare will negotiate prices for Ozempic and 14 other drugs in 2025, with prices taking effect in 2026. Negotiations could lower prices for Medicare ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.